Hematoxylin binds to mutant calreticulin and disrupts its abnormal interaction with thrombopoietin receptor

Somatic mutations of calreticulin (CALR) have been identified as a main disease driver of myeloproliferative neoplasms, suggesting that development of drugs targeting mutant CALR is of great significance. Site-directed mutagenesis in the N-glycan binding domain (GBD) abolishes the ability of mutant...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood
Autors principals: Jia, Ruochen, Balligand, Thomas, Atamanyuk, Vasyl, Nivarthi, Harini, Xu, Erica, Kutzner, Leon, Weinzierl, Jakob, Nedelec, Audrey, Kubicek, Stefan, Lesyk, Roman, Zagrijtschuk, Oleh, Constantinescu, Stefan N., Kralovics, Robert
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2021
Matèries:
Myeloid Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8118640/
https://ncbi.nlm.nih.gov/pubmed/33202418
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020006264
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars